

Pathology and Laboratory Medicine Memorandum

To: Physicians and Health Service Directors, Central Zone
Nova Scotia Laboratories

From: Dr. Amy Lou Clinical Biochemist, Division of Clinical Chemistry
Mrs. Catherine Lambert, Manager Community Based Laboratories
Ms. Cindy Andrews, Manager Core Laboratory

Date: January 14, 2019

Subject: **Discontinuation of Urine Glucose testing in the Central Zone**

Effective February 4, 2019 quantitative urine glucose testing will be discontinued. Semi –quantitative glucose testing continues to be included in a urinalysis panel.

The rationale for this decision is as follows:

Elevated urine glucose concentration reflects either the presence of hyperglycemia or a defect in proximal tubule function.

For hyperglycemia, quantitative urine glucose testing has essentially been replaced by more accurate and reliable blood glucose determinations. For some very rare conditions that adversely affect proximal tubule function, such as Fanconi syndrome, Wilson disease, hereditary glucosuria, and interstitial nephritis, Semi –quantitative glucose testing in a urinalysis panel can be requested.

If you have any questions, please contact Dr. Amy Lou at (902)473-1528.